Nasal polyps are common, affecting up to 4% of the general population, and can affect quality of life, but are usually benign. However, a new study suggests that when they occur in older patients (≥ ...

-- American Journal of Rhinology & Allergy Article Highlights Company's Bi-directional Delivery Technology for Chronic Rhinosinusitis with Nasal Polyps; Technology Significantly and Progressively ...

People with allergies or asthma may be at risk for developing nasal polyps: tiny, grapelike sacs that block nasal passages, making it tough for a person to smell or taste. But a new procedure restores ...

An exhalation system with fluticasone was shown to significantly reduce nasal polyp score at 4 and 16 weeks compared with placebo, with improvements also observed in several patient-reported outcomes.

Patients with severe chronic rhinosinusitis with nasal polyps achieved significant improvements in health-related quality of life (HRQOL) and general health status with dupilumab treatment after 52 ...

– Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation – – Xolair is now FDA-approved across three diseases and ...

The U.S. Food and Drug Administration today approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis ...

Recently published Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of ...

Please provide your email address to receive an email when new articles are posted on . The Exhalation Delivery System reaches inflamed areas of the nasal cavity and sinuses that other sprays miss.

Congestion, headaches, and sinus infections burden the lives of nearly 30 million Americans suffering from chronic sinusitis each year. For Lizette Serrano, relentless allergies and asthma attacks led ...